HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by St. John Sutton, M. Articles by Freed, M. Search for Related Content PubMed PubMed Citation Articles by St. John Sutton, M. Articles by Freed, M. Social Bookmarking                What's this?

A Comparison of the Effects of Rosiglitazone and Glyburide on Cardiovascular Function and Glycemic Control in Patients With Type 2 Diabetes

¹ University of Pennsylvania Medical Center, Philadelphia, Pennsylvania
² Creighton University, Omaha, Nebraska
³ State University of New York School of Medicine at Buffalo, Buffalo, New York
⁴ GlaxoSmithKline, Collegeville, Pennsylvania

OBJECTIVE—This open-label, active-controlled study investigated the cardiac safety and antihyperglycemic effect of rosiglitazone (RSG) in patients with type 2 diabetes.

RESEARCH DESIGN AND METHODS—Of the 203 patients randomly assigned to RSG (4 mg b.i.d.) or glyburide (GLB) (titrated to achieve optimal glycemic control for the first 8 weeks only to limit the risk of hypoglycemia; mean 10.5 mg/day), 118 had an echocardiogram performed at week 52. Left ventricular (LV) mass index, ejection fraction, and left ventricular end-diastolic volume were assessed by M-mode echocardiography at baseline and weeks 12, 28, and 52; 24-h ambulatory blood pressure was assessed at baseline and at weeks 28 and 52. Glycemic control was assessed by measuring fasting plasma glucose (FPG) and HbA_1c.

RESULTS—Neither treatment produced an increase in LV mass index that exceeded 1 SD. Ejection fraction did not change in either group. Both groups had clinically insignificant increases in LV end-diastolic volume. RSG, but not GLB, caused a statistically significant reduction in ambulatory diastolic blood pressure. Both treatments reduced HbA_1c and FPG.

CONCLUSIONS—A total of 52 weeks of therapy with RSG (4 mg b.i.d.) did not adversely affect cardiac structure or function in patients with type 2 diabetes and produced significant and sustained reductions in hyperglycemia. Decreases in ambulatory diastolic blood pressure with RSG were superior to those with GLB.

Abbreviations: ACEI, ACE inhibitor • AE, adverse event • BP, blood pressure • ECG, electrocardiogram • EF, ejection fraction • FPG, fasting plasma glucose • GLB, glyburide • ITT, intent to treat • LOCF, last observation carried forward • LV, left ventricular • LVEDV, LV end-diastolic volume • LVM, LV mass • LVMI, LV mass index • MR, mitral regurgitation • RSG, rosiglitazone

CiteULike    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				The DREAM Trial Investigators Effects of Ramipril and Rosiglitazone on Cardiovascular and Renal Outcomes in People With Impaired Glucose Tolerance or Impaired Fasting Glucose: Results of the Diabetes REduction Assessment with ramipril and rosiglitazone Medication (DREAM) trial Diabetes Care, May 1, 2008; 31(5): 1007 - 1014. [Abstract] [Full Text] [PDF]

				D. K. McGuire and S. E. Inzucchi New Drugs for the Treatment of Diabetes Mellitus: Part I: Thiazolidinediones and Their Evolving Cardiovascular Implications Circulation, January 22, 2008; 117(3): 440 - 449. [Full Text] [PDF]

				E. Erdmann and R. G. Wilcox Weighing up the cardiovascular benefits of thiazolidinedione therapy: the impact of increased risk of heart failure Eur. Heart J., January 1, 2008; 29(1): 12 - 20. [Abstract] [Full Text] [PDF]

				S. Singh, Y. K. Loke, and C. D. Furberg Thiazolidinediones and Heart Failure: A teleo-analysis Diabetes Care, August 1, 2007; 30(8): 2148 - 2153. [Abstract] [Full Text] [PDF]

				J. L. Kitzmiller, L. Dang-Kilduff, and M. M. Taslimi Gestational Diabetes After Delivery: Short-term management and long-term risks Diabetes Care, July 1, 2007; 30(Supplement_2): S225 - S235. [Full Text] [PDF]

				S. E. Nissen and K. Wolski Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes N. Engl. J. Med., June 14, 2007; 356(24): 2457 - 2471. [Abstract] [Full Text] [PDF]

				M. C. Granberry, J. B. Hawkins, and A. M. Franks Thiazolidinediones in patients with type 2 diabetes mellitus and heart failure Am. J. Health Syst. Pharm., May 1, 2007; 64(9): 931 - 936. [Abstract] [Full Text] [PDF]

				J. Lindenfeld and F. A. Masoudi Fluid Retention With Thiazolidinediones: Does the Mechanism Influence the Outcome? J. Am. Coll. Cardiol., April 24, 2007; 49(16): 1705 - 1707. [Full Text] [PDF]

				H. J. Dargie, P. R. Hildebrandt, G. A.J. Riegger, J. J.V. McMurray, S. O. McMorn, J. N. Roberts, A. Zambanini, and J. P.H. Wilding A Randomized, Placebo-Controlled Trial Assessing the Effects of Rosiglitazone on Echocardiographic Function and Cardiac Status in Type 2 Diabetic Patients With New York Heart Association Functional Class I or II Heart Failure J. Am. Coll. Cardiol., April 24, 2007; 49(16): 1696 - 1704. [Abstract] [Full Text] [PDF]

				G. Hansmann, R. A. Wagner, S. Schellong, V. A. de Jesus Perez, T. Urashima, L. Wang, A. Y. Sheikh, R. S. Suen, D. J. Stewart, and M. Rabinovitch Pulmonary Arterial Hypertension Is Linked to Insulin Resistance and Reversed by Peroxisome Proliferator-Activated Receptor-{gamma} Activation Circulation, March 13, 2007; 115(10): 1275 - 1284. [Abstract] [Full Text] [PDF]

				G. C. Mistry, A. J. Bergman, W.-L. Luo, C. Cilissen, W. Haazen, M. J. Davies, K. M. Gottesdiener, J. A. Wagner, and G. A. Herman Multiple-Dose Administration of Sitagliptin, a Dipeptidyl Peptidase-4 Inhibitor, Does Not Alter the Single-Dose Pharmacokinetics of Rosiglitazone in Healthy Subjects J. Clin. Pharmacol., February 1, 2007; 47(2): 159 - 164. [Abstract] [Full Text] [PDF]

				A. J.M. Rennings, P. Smits, M. W. Stewart, and C. J. Tack Fluid retention and vascular effects of rosiglitazone in obese, insulin-resistant, nondiabetic subjects. Diabetes Care, March 1, 2006; 29(3): 581 - 587. [Abstract] [Full Text] [PDF]

				F. Blaschke, Y. Takata, E. Caglayan, R. E. Law, and W. A. Hsueh Obesity, Peroxisome Proliferator-Activated Receptor, and Atherosclerosis in Type 2 Diabetes Arterioscler. Thromb. Vasc. Biol., January 1, 2006; 26(1): 28 - 40. [Abstract] [Full Text] [PDF]

				R. Lautamaki, K.E. J. Airaksinen, M. Seppanen, J. Toikka, M. Luotolahti, E. Ball, R. Borra, R. Harkonen, P. Iozzo, M. Stewart, et al. Rosiglitazone Improves Myocardial Glucose Uptake in Patients With Type 2 Diabetes and Coronary Artery Disease: A 16-Week Randomized, Double-Blind, Placebo-Controlled Study Diabetes, September 1, 2005; 54(9): 2787 - 2794. [Abstract] [Full Text] [PDF]

				S. Z. Duan, C. Y. Ivashchenko, M. W. Russell, D. S. Milstone, and R. M. Mortensen Cardiomyocyte-Specific Knockout and Agonist of Peroxisome Proliferator-Activated Receptor-{gamma} Both Induce Cardiac Hypertrophy in Mice Circ. Res., August 19, 2005; 97(4): 372 - 379. [Abstract] [Full Text] [PDF]

				M. N. Cook, C. J. Girman, P. P. Stein, C. M. Alexander, and R. R. Holman Glycemic Control Continues to Deteriorate After Sulfonylureas Are Added to Metformin Among Patients With Type 2 Diabetes Diabetes Care, May 1, 2005; 28(5): 995 - 1000. [Abstract] [Full Text] [PDF]

				A. Harte, P. McTernan, R. Chetty, S. Coppack, J. Katz, S. Smith, and S. Kumar Insulin-Mediated Upregulation of the Renin Angiotensin System in Human Subcutaneous Adipocytes Is Reduced by Rosiglitazone Circulation, April 19, 2005; 111(15): 1954 - 1961. [Abstract] [Full Text] [PDF]

				M. H. Tan, A. Baksi, B. Krahulec, P. Kubalski, A. Stankiewicz, R. Urquhart, G. Edwards, D. Johns, and for the GLAL Study Group Comparison of Pioglitazone and Gliclazide in Sustaining Glycemic Control Over 2 Years in Patients With Type 2 Diabetes Diabetes Care, March 1, 2005; 28(3): 544 - 550. [Abstract] [Full Text] [PDF]

				F. A. Masoudi, S. E. Inzucchi, Y. Wang, E. P. Havranek, J. M. Foody, and H. M. Krumholz Thiazolidinediones, Metformin, and Outcomes in Older Patients With Diabetes and Heart Failure: An Observational Study Circulation, February 8, 2005; 111(5): 583 - 590. [Abstract] [Full Text] [PDF]

				N. Singh Rosiglitazone and Heart Failure: Long-Term Vigilance Journal of Cardiovascular Pharmacology and Therapeutics, March 1, 2004; 9(1): 21 - 25. [Abstract] [PDF]

				W. A. Hsueh and D. Bruemmer Peroxisome Proliferator-Activated Receptor {gamma}: Implications for Cardiovascular Disease Hypertension, February 1, 2004; 43(2): 297 - 305. [Abstract] [Full Text] [PDF]

				R. W. Nesto, D. Bell, R. O. Bonow, V. Fonseca, S. M. Grundy, E. S. Horton, M. Le Winter, D. Porte, C. F. Semenkovich, S. Smith, et al. Thiazolidinedione Use, Fluid Retention, and Congestive Heart Failure: A consensus statement from the American Heart Association and American Diabetes Association Diabetes Care, January 1, 2004; 27(1): 256 - 263. [Full Text] [PDF]

				R. W. Nesto, D. Bell, R. O. Bonow, V. Fonseca, S. M. Grundy, E. S. Horton, M. Le Winter, D. Porte, C. F. Semenkovich, S. Smith, et al. Thiazolidinedione Use, Fluid Retention, and Congestive Heart Failure: A Consensus Statement From the American Heart Association and American Diabetes Association Circulation, December 9, 2003; 108(23): 2941 - 2948. [Full Text] [PDF]

				W. H. W. Tang, G. S. Francis, B. J. Hoogwerf, and J. B. Young Fluid retention after initiation of thiazolidinedione therapy in diabetic patients with established chronic heart failure J. Am. Coll. Cardiol., April 16, 2003; 41(8): 1394 - 1398. [Abstract] [Full Text] [PDF]